ClinicalTrials.gg
CompletedNCT00996216ENABLE-ALLUpdated Dec 6, 2013Results posted

Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390

A Phase 3 interventional study of Eltrombopag and Antiviral therapy in Hepatitis C, sponsored by GlaxoSmithKline. Completed at 28 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-06.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Hepatitis C by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Hepatitis C · GlaxoSmithKline.

Enrollment
18th of 20
27 · median 53
Started
2009
with 1 other
Phase 3
6 of 21
none open now
Registered
12th of 21
by date

Among the 21 studies in Hepatitis C by GlaxoSmithKline, this one is the 18th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2009, is one of 6 in phase 3, and was the 12th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 21 studies in Hepatitis C by GlaxoSmithKline is open now. The open studies under Hepatitis C, anywhere →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Hepatitis C by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count. Platelet count to be maintained at a level sufficient to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose reductions, and to avoid permanent discontinuation of antiviral therapy.

03

Conditions studied

  • Hepatitis C

Keywords

  • Peginterferon
  • Platelets
  • Ribavirin
  • Hepatitis C-related thrombocytopenia
  • Thrombocytopenia
  • Hepatitis C
  • Thrombopoietin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior participation in protocol TPL103922 or TPL108390 and completed the Week 24 Follow Up Visit in TPL103922 or TPL108390
  • Male or female ≥18 years old
  • Evidence of chronic infection
  • While participating in TPL103922 or TPL108390, discontinued from study drug due to thrombocytopenia
  • Appropriate candidate for antiviral therapy with pegylated interferon plus ribavirin
  • count \<75,000
  • Fertile males and females must use two forms of effective during treatment and for 24 weeks after treatment
  • Ability to understand and comply with the protocol requirements and instructions
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Decompensated liver disease
  • Known , intolerance, or allergy to interferon, ribavirin, eltrombopag, or their ingredients
  • History of bleeding from oesophageal or gastric varices
  • History of arterial or venous thrombosis and two or more of the following risk factors: hereditary thrombophilic disorders; hormone replacement therapy; systemic (containing estrogen); smoking; diabetes; hypercholesterolemia; medication for hypertension or cancer
  • Pre-existing cardiac disease (congestive heart failure Grade III/IV) or arrhythmias known to involve the risk of thromboembolic events (e.g. atrial fibrillation)
  • Evidence of hepatocellular carcinoma
  • or infection
  • Therapy with anti-neoplastic or immunomodulatory treatment within six months prior to eltrombopag therapy
  • diagnosed or treated within the past five years. Except for localized basal or squamous cell carcinoma treated by local excision or malignancies that were adequately treated and, in the opinion of the oncologist, have an excellent chance of cancer-free survival.
  • Pregnant or nursing women
  • Men with a female partner who is pregnant
  • History of alcohol/drug abuse or dependence within six months of the study start unless participating in a controlled rehabilitation programme.
  • Treatment with an drug or interferon within 30 days or 5 half-lives (whichever is longer) of the screening visit
  • History or clumping that prevents reliable measurement of platelet counts
  • Evidence of portal vein thrombosis within three months of baseline visit
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Open-label eltrombopag

    Open-label eltrombopag with dose titrations to support adequate platelet counts.

    Drug: Eltrombopag · Drug: Antiviral therapy

Interventions

  • Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.

    Also known as: Promacta

  • DrugAntiviral therapy

    Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part 1

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs and SAEs.

    Time frame: From the start of investigational product up to the start of antiviral therapy (up to 9 weeks; median of 21 days)

  2. Number of Participants With Any AE and Any SAE in Part 2

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs and SAEs.

    Time frame: From the date of initiation of antiviral therapy (Antiviral Baseline Visit [between Study Day 14 and Study Day 65]) to the completion of the follow-up period (up to Week 96/WD)

  3. Number of Participants With the Indicated Worst-case Division of Acquired Immune Deficiency Syndrome (DAIDS) Grade Increases From Screening for the Indicated Clinical Chemistry Parameters During Part 1

    Blood samples were collected for the measurement of clinical chemistry parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.

    Time frame: From Screening up to the start of antiviral therapy (up to 9 weeks; median of 21 days)

  4. Number of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Clinical Chemistry Parameter During Part 2

    Blood samples were collected for the measurement of clinical chemistry parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.

    Time frame: From Day 0 of Part 2 (Antiviral Baseline Visit [between Study Day 14 and Study Day 65) to the completion of the follow-up period (up to Week 96/WD)

  5. Number of Participants With the Indicated Worst-case DAIDS Grade Increases From Screening for the Indicated Hematology Parameters During Part 1

    Blood samples were collected for the measurement of hematology parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.

    Time frame: From Screening up to the start of antiviral therapy (up to 9 weeks; median of 21 days)

  6. Number of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Hematology Parameters During Part 2

    Blood samples were collected for the measurement of hematology chemistry parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.

    Time frame: From Day 0 of Part 2 (Antiviral Baseline Visit [between Study Day 14 and Study Day 65) to the completion of the follow-up period (up to Week 96/WD)

  7. Number of Participants With a Decrease in Visual Acuity During Parts 1 and 2

    Visual acuity (VA) is defined as acuteness or clearness of vision.

    Time frame: From the start of investigational product up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)

  8. Number of Participants With the Indicated Change in logMAR Scale Values During Parts 1 and 2

    LogMAR (logarithm of the minimum angle of resolution) charts are used to measure an individual's visual acuity. LogMAR, expressed as the (decadic) logarithm of the minimum angle of resolution (range from +1.00 to -0.30), converts the geometric sequence of a traditional chart to a linear scale. As there are 5 letters per line, the total score for a line on the LogMAR chart represents a change of 0.1 log units.

    Time frame: From the start of investigational product up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)

  9. Number of Participants With a logMAR Change >=0.15 During Parts 1 and 2

    LogMAR (logarithm of the minimum angle of resolution) charts are used to measure an individual's visual acuity. LogMAR, expressed as the (decadic) logarithm of the minimum angle of resolution (range from +1.00 to -0.30), converts the geometric sequence of a traditional chart to a linear scale. As there are 5 letters per line, the total score for a line on the LogMAR chart represents a change of 0.1 log units.

    Time frame: From the start of investigational product up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)

Secondary outcomes

  1. Platelet Counts at the Indicated Time Points

    Blood samples were collected for the measurement of platelet count. For each participant, the duration of Part 1 treatment varies between 2 and 9 weeks.

    Time frame: From the start of investigational product up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)

  2. Number of Particpants Who Initiated Antiviral Therapy

    The number of participants who completed the Pre-antiviral Phase (Part 1) and proceeded to the Antiviral Phase (Part 2) are summarized.

    Time frame: From the start of the investigational product up to 9 weeks (median of 21 days)

  3. Number of Participants Achieving Antiviral Treatment Milestones of Sustained Virological Response (SVR), Rapid Virological Response (RVR), Early Virological Response (EVR), and End of Treatment Response (ETR)

    SVR is defined as non-detectable Hepatitis C virus (HCV) ribonucleic acid (RNA) at 24 weeks post-completion of the planned treatment period (i.e., Week 48 or 72 for genotype 2/3 or Week 72 for non-genotype 2/3). RVR is defined as undetectable HCV RNA after 4 weeks of antiviral treatment. EVR is defined as clinically significant reduction in HCV RNA (\>=2 log10 drop or undetectable) after 12 weeks of antiviral treatment. ETR is defined as undetectable HCV RNA at the end of antiviral treatment.

    Time frame: From the start of investigational product in Part 2 up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)

07

Results

Posted Dec 6, 2013

Participant flow

10\^9 cells (Giga) per liter=Gi/L; participants=par.; polyethylene glycol=Peg; interferon=INF.

Part 1 (Pre-Antiviral Treatment Phase)
Participant flow — Part 1 (Pre-Antiviral Treatment Phase)
MilestoneEltrombopag
Started27
Completed26
Not completed1
Withdrew: Withdrawal by subject1
Part 2 (Antiviral Treatment Phase)
Participant flow — Part 2 (Antiviral Treatment Phase)
MilestoneEltrombopag
Started25
Completed21
Not completed4
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject1

Outcome measures

SecondaryPlatelet Counts at the Indicated Time Points

Blood samples were collected for the measurement of platelet count. For each participant, the duration of Part 1 treatment varies between 2 and 9 weeks.

Time frame:
From the start of investigational product up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)
Reported as:
Mean · Gi/L
Platelet Counts at the Indicated Time Points
Gi/LEltrombopag
Screening, n=2753.1 ± 12.90
Part 1/Day 1, n=2755.9 ± 18.69
Part 1/Week 1, n=2573.3 ± 29.27
Part 1/Week 2, n=1683.2 ± 27.90
Part 1/Week 3, n=873.4 ± 26.53
Part 1/Week 4, n=775.6 ± 19.95
Part 1/Week 5, n=572.2 ± 18.29
Part 1/Week 6, n=581.6 ± 14.45
Part 1/Week 7, n=576.2 ± 19.88
Part 1/Week 8, n=391.7 ± 22.81
Part 2/Antiviral Baseline, n=25132.9 ± 33.72
Part 2/Week 1, n=25106.7 ± 37.80
Part 2/Week 2, n=2593.2 ± 42.98
Part 2/Week 4, n=2380.5 ± 30.64
Part 2/Week 8, n=2180.3 ± 24.40
Part 2/Week 12, n=2083.1 ± 31.72
Part 2/Week 16, n=1685.8 ± 27.61
Part 2/Week 20, n=1475.3 ± 22.54
Part 2/Week 24, n=1178.6 ± 30.63
Part 2/Week 28, n=990.3 ± 50.09
Part 2/Week 32, n=786.1 ± 72.12
Part 2/Week 36, n=676.8 ± 53.77
Part 2/Week 40, n=555.8 ± 27.65
Part 2/Week 44, n=554.4 ± 29.18
Part 2/Week 48, n=268.0 ± 29.70
Part 2/Week 52, n=149.0 ± NA
Part 2/Week 56, n=147.0 ± NA
Part 2/Week 60, n=143.0 ± NA
Part 2/Week 64, n=143.0 ± NA
Part 2/Week 68, n=144.0 ± NA
Post-treatment/4 Week Follow-up, n=2377.8 ± 33.48
Post-treatment/24 Week Follow-up, n=2252.5 ± 17.91
Investigational product discontinuation, n=2691.3 ± 38.78
Maximum value post-Baseline, n=26145.5 ± 43.68
SecondaryNumber of Particpants Who Initiated Antiviral Therapy

The number of participants who completed the Pre-antiviral Phase (Part 1) and proceeded to the Antiviral Phase (Part 2) are summarized.

Time frame:
From the start of the investigational product up to 9 weeks (median of 21 days)
Reported as:
Number · Participants
Number of Particpants Who Initiated Antiviral Therapy
ParticipantsEltrombopag
Yes25
No2
PrimaryNumber of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part 1

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs and SAEs.

Time frame:
From the start of investigational product up to the start of antiviral therapy (up to 9 weeks; median of 21 days)
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part 1
ParticipantsEltrombopag
Any SAE0
Any AE9
PrimaryNumber of Participants With Any AE and Any SAE in Part 2

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs and SAEs.

Time frame:
From the date of initiation of antiviral therapy (Antiviral Baseline Visit [between Study Day 14 and Study Day 65]) to the completion of the follow-up period (up to Week 96/WD)
Reported as:
Number · Participants
Number of Participants With Any AE and Any SAE in Part 2
ParticipantsEltrombopag
Any SAE5
Any AE25
PrimaryNumber of Participants With the Indicated Worst-case Division of Acquired Immune Deficiency Syndrome (DAIDS) Grade Increases From Screening for the Indicated Clinical Chemistry Parameters During Part 1

Blood samples were collected for the measurement of clinical chemistry parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.

Time frame:
From Screening up to the start of antiviral therapy (up to 9 weeks; median of 21 days)
Reported as:
Number · Participants
Number of Participants With the Indicated Worst-case Division of Acquired Immune Deficiency Syndrome (DAIDS) Grade Increases From Screening for the Indicated Clinical Chemistry Parameters During Part 1
ParticipantsEltrombopag
Alanine amino transferase, Any Increase2
Alanine amino transferase, Increase to Grade 11
Alanine amino transferase, Increase to Grade 20
Alanine amino transferase, Increase to Grade 31
Alanine amino transferase, Increase to Grade 40
Albumin, Any Increase1
Albumin, Increase to Grade 11
Albumin, Increase to Grade 20
Albumin, Increase to Grade 30
Albumin, Increase to Grade 40
Alkaline phosphatase, Any Increase1
Alkaline phosphatase, Increase to Grade 11
Alkaline phosphatase, Increase to Grade 20
Alkaline phosphatase, Increase to Grade 30
Alkaline phosphatase, Increase to Grade 40
Aspartate amino transferase, Any Increase2
Aspartate amino transferase, Increase to Grade 12
Aspartate amino transferase, Increase to Grade 20
Aspartate amino transferase, Increase to Grade 30
Aspartate amino transferase, Increase to Grade 40
Creatinine, Any Increase0
Creatinine, Increase to Grade 10
Creatinine, Increase to Grade 20
Creatinine, Increase to Grade 30
Creatinine, Increase to Grade 40
Total bilirubin, Any Increase10
Total bilirubin, Increase to Grade 16
Total bilirubin, Increase to Grade 24
Total bilirubin, Increase to Grade 30
Total bilirubin, Increase to Grade 40
Uric acid, Any Increase3
Uric acid, Increase to Grade 13
Uric acid, Increase to Grade 20
Uric acid, Increase to Grade 30
Uric acid, Increase to Grade 40
PrimaryNumber of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Clinical Chemistry Parameter During Part 2

Blood samples were collected for the measurement of clinical chemistry parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.

Time frame:
From Day 0 of Part 2 (Antiviral Baseline Visit [between Study Day 14 and Study Day 65) to the completion of the follow-up period (up to Week 96/WD)
Reported as:
Number · Participants
Number of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Clinical Chemistry Parameter During Part 2
ParticipantsEltrombopag
Alanine amino transferase, Any Increase4
Alanine amino transferase, Increase to Grade 13
Alanine amino transferase, Increase to Grade 20
Alanine amino transferase, Increase to Grade 31
Alanine amino transferase, Increase to Grade 40
Albumin, Any Increase9
Albumin, Increase to Grade 14
Albumin, Increase to Grade 25
Albumin, Increase to Grade 30
Albumin, Increase to Grade 40
Alkaline phosphatase, Any Increase7
Alkaline phosphatase, Increase to Grade 17
Alkaline phosphatase, Increase to Grade 20
Alkaline phosphatase, Increase to Grade 30
Alkaline phosphatase, Increase to Grade 40
Aspartate amino transferase, Any Increase9
Aspartate amino transferase, Increase to Grade 11
Aspartate amino transferase, Increase to Grade 28
Aspartate amino transferase, Increase to Grade 30
Aspartate amino transferase, Increase to Grade 40
Creatinine, Any Increase1
Creatinine, Increase to Grade 10
Creatinine, Increase to Grade 20
Creatinine, Increase to Grade 31
Creatinine, Increase to Grade 40
Total bilirubin, Any Increase16
Total bilirubin, Increase to Grade 11
Total bilirubin, Increase to Grade 25
Total bilirubin, Increase to Grade 310
Total bilirubin, Increase to Grade 40
Uric acid, Any Increase5
Uric acid, Increase to Grade 14
Uric acid, Increase to Grade 21
Uric acid, Increase to Grade 30
Uric acid, Increase to Grade 40
PrimaryNumber of Participants With the Indicated Worst-case DAIDS Grade Increases From Screening for the Indicated Hematology Parameters During Part 1

Blood samples were collected for the measurement of hematology parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.

Time frame:
From Screening up to the start of antiviral therapy (up to 9 weeks; median of 21 days)
Reported as:
Number · Participants
Number of Participants With the Indicated Worst-case DAIDS Grade Increases From Screening for the Indicated Hematology Parameters During Part 1
ParticipantsEltrombopag
Hemoglobin, Any Increase2
Hemoglobin, Increase to Grade 12
Hemoglobin, Increase to Grade 20
Hemoglobin, Increase to Grade 30
Hemoglobin, Increase to Grade 40
Lymphocytes, Any Increase3
Lymphocytes, Increase to Grade 11
Lymphocytes, Increase to Grade 21
Lymphocytes, Increase to Grade 31
Lymphocytes, Increase to Grade 40
Total neutrophils, Any Increase3
Total neutrophils, Increase to Grade 13
Total neutrophils, Increase to Grade 20
Total neutrophils, Increase to Grade 30
Total neutrophils, Increase to Grade 40
White Blood cell count, Any Increase2
White Blood cell count, Increase to Grade 10
White Blood cell count, Increase to Grade 22
White Blood cell count, Increase to Grade 30
White Blood cell count, Increase to Grade 40
PrimaryNumber of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Hematology Parameters During Part 2

Blood samples were collected for the measurement of hematology chemistry parameters. The DAIDS grades are utilized for measuring the severity of AEs. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening.

Time frame:
From Day 0 of Part 2 (Antiviral Baseline Visit [between Study Day 14 and Study Day 65) to the completion of the follow-up period (up to Week 96/WD)
Reported as:
Number · Participants
Number of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Hematology Parameters During Part 2
ParticipantsEltrombopag
Hemoglobin, Any Increase12
Hemoglobin, Increase to Grade 11
Hemoglobin, Increase to Grade 25
Hemoglobin, Increase to Grade 35
Hemoglobin, Increase to Grade 41
Lymphocytes, Any Increase15
Lymphocytes, Increase to Grade 11
Lymphocytes, Increase to Grade 23
Lymphocytes, Increase to Grade 33
Lymphocytes, Increase to Grade 48
Total neutrophils, Any Increase23
Total neutrophils, Increase to Grade 14
Total neutrophils, Increase to Grade 210
Total neutrophils, Increase to Grade 38
Total neutrophils, Increase to Grade 41
White Blood Cell count, Any Increase20
White Blood Cell count, Increase to Grade 15
White Blood Cell count, Increase to Grade 27
White Blood Cell count, Increase to Grade 37
White Blood Cell count, Increase to Grade 41
PrimaryNumber of Participants With a Decrease in Visual Acuity During Parts 1 and 2

Visual acuity (VA) is defined as acuteness or clearness of vision.

Time frame:
From the start of investigational product up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)
Reported as:
Number · Participants
Number of Participants With a Decrease in Visual Acuity During Parts 1 and 2
ParticipantsEltrombopag
Decrease in Visual Acuity, Yes10
Decrease in Visual Acuity, No15
Decrease in Visual Acuity, Missing or Unknown2
PrimaryNumber of Participants With the Indicated Change in logMAR Scale Values During Parts 1 and 2

LogMAR (logarithm of the minimum angle of resolution) charts are used to measure an individual's visual acuity. LogMAR, expressed as the (decadic) logarithm of the minimum angle of resolution (range from +1.00 to -0.30), converts the geometric sequence of a traditional chart to a linear scale. As there are 5 letters per line, the total score for a line on the LogMAR chart represents a change of 0.1 log units.

Time frame:
From the start of investigational product up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)
Reported as:
Number · Participants
Number of Participants With the Indicated Change in logMAR Scale Values During Parts 1 and 2
ParticipantsEltrombopag
logMAR Changes, <0.10 (No Change or Improvement)15
logMAR Changes, >=0.10 to <0.20 (Loss of 1 Line)6
logMAR Changes, >=0.20 to <0.30 (Loss of 2 Lines)3
logMAR Changes, >=0.30 (Loss of 3 Lines or more)1
logMAR Changes, Missing or Unknown2
PrimaryNumber of Participants With a logMAR Change >=0.15 During Parts 1 and 2

LogMAR (logarithm of the minimum angle of resolution) charts are used to measure an individual's visual acuity. LogMAR, expressed as the (decadic) logarithm of the minimum angle of resolution (range from +1.00 to -0.30), converts the geometric sequence of a traditional chart to a linear scale. As there are 5 letters per line, the total score for a line on the LogMAR chart represents a change of 0.1 log units.

Time frame:
From the start of investigational product up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)
Reported as:
Number · Participants
Number of Participants With a logMAR Change >=0.15 During Parts 1 and 2
ParticipantsEltrombopag
logMAR change, Yes4
logMAR change, No21
logMAR change, Missing or Unknown2
SecondaryNumber of Participants Achieving Antiviral Treatment Milestones of Sustained Virological Response (SVR), Rapid Virological Response (RVR), Early Virological Response (EVR), and End of Treatment Response (ETR)

SVR is defined as non-detectable Hepatitis C virus (HCV) ribonucleic acid (RNA) at 24 weeks post-completion of the planned treatment period (i.e., Week 48 or 72 for genotype 2/3 or Week 72 for non-genotype 2/3). RVR is defined as undetectable HCV RNA after 4 weeks of antiviral treatment. EVR is defined as clinically significant reduction in HCV RNA (\>=2 log10 drop or undetectable) after 12 weeks of antiviral treatment. ETR is defined as undetectable HCV RNA at the end of antiviral treatment.

Time frame:
From the start of investigational product in Part 2 up to the 24-week follow-up visit after the last dose in Part 2 or early withdrawal (up to 96 weeks)
Reported as:
Number · Participants
Number of Participants Achieving Antiviral Treatment Milestones of Sustained Virological Response (SVR), Rapid Virological Response (RVR), Early Virological Response (EVR), and End of Treatment Response (ETR)
ParticipantsEltrombopag
SVR, Yes, n=174
SVR, No, n=1713
RVR, Yes, n=123
RVR, No, n=129
EVR, Yes, n=1515
EVR, No, n=150
ETR, Yes, n=219
ETR, No, n=2112

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the end of the 24-week follow up period (up to Week 96/WD).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag (Part 1)—0/27 (0%)9/27 (33.3%)
Eltrombopag (Part 2)—5/25 (20%)25/25 (100%)
Most frequent serious events
Most frequent serious events
EventEltrombopag (Part 1)Eltrombopag (Part 2)
Hepatic encephalopathyNervous system disorders0/271/25
Myoclonic epilepsyNervous system disorders0/271/25
ThrombocytopeniaBlood and lymphatic system disorders0/271/25
Upper gastrointestinal haemorrhageGastrointestinal disorders0/271/25
CellulitisInfections and infestations0/271/25
Metabolic disorderMetabolism and nutrition disorders0/271/25
Most frequent other events
Showing 10 of 125
Most frequent other events
EventEltrombopag (Part 1)Eltrombopag (Part 2)
PyrexiaGeneral disorders0/279/25
NauseaGastrointestinal disorders2/277/25
HeadacheNervous system disorders2/277/25
LeukopeniaBlood and lymphatic system disorders0/277/25
FatigueGeneral disorders0/277/25
AnaemiaBlood and lymphatic system disorders1/276/25
AstheniaGeneral disorders1/275/25
Influenza like illnessGeneral disorders0/275/25
DiarrhoeaGastrointestinal disorders0/274/25
VomitingGastrointestinal disorders0/274/25

Baseline characteristics

Age Continuous
Age Continuous(Years)Eltrombopag
Mean51.3 ± 7.70
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag
Female7
Male20
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Eltrombopag
Central/South Asian Heritage2
White25
08

Study locations

28 sites
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    New Haven, Connecticut 06520, United States
  • GSK Investigational Site
    Honolulu, Hawaii 96817, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    Nashville, Tennessee 37212, United States
  • GSK Investigational Site
    Seattle, Washington 98111, United States
  • GSK Investigational Site
    Camperdown, New South Wales 2050, Australia
  • GSK Investigational Site
    Randwick, New South Wales 2031, Australia
  • GSK Investigational Site
    Herston, Queensland 4029, Australia
  • GSK Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • GSK Investigational Site
    Montreal, Quebec H2X 3J4, Canada
  • GSK Investigational Site
    Marseille Cedex 08, 13285, France
  • GSK Investigational Site
    Nice cedex 3, 06202, France
  • GSK Investigational Site
    Pessac Cedex, 33604, France
  • GSK Investigational Site
    Freiburg, Baden-Wuerttemberg 79106, Germany
  • GSK Investigational Site
    Ulm, Baden-Wuerttemberg 89081, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81675, Germany
  • GSK Investigational Site
    Duesseldorf, Nordrhein-Westfalen 40225, Germany
  • GSK Investigational Site
    Berlin, 10969, Germany
  • GSK Investigational Site
    Athens, 10676, Greece
  • GSK Investigational Site
    Bologna, Emilia-Romagna 40138, Italy
  • GSK Investigational Site
    Genova, Liguria 16132, Italy
  • GSK Investigational Site
    Milano, Lombardia 20157, Italy
  • GSK Investigational Site
    Lahore, 54600, Pakistan
  • GSK Investigational Site
    La Coruña, 15006, Spain
  • GSK Investigational Site
    Madrid, 28029, Spain
  • GSK Investigational Site
    Pontevedra, 36071, Spain
  • GSK Investigational Site
    Valencia, 46010, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2009
First posted
Oct 16, 2009
Start
Sep 2009
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
Dec 6, 2013
Last update
Dec 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00996216
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 16, 2009
Start date
Sep 2009
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Dec 6, 2013
Last update
Dec 6, 2013

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion